CN106133519B - Gip上升抑制剂的评价或选择方法 - Google Patents

Gip上升抑制剂的评价或选择方法 Download PDF

Info

Publication number
CN106133519B
CN106133519B CN201580015560.7A CN201580015560A CN106133519B CN 106133519 B CN106133519 B CN 106133519B CN 201580015560 A CN201580015560 A CN 201580015560A CN 106133519 B CN106133519 B CN 106133519B
Authority
CN
China
Prior art keywords
fabp4
protein
fabp5
genes
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580015560.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106133519A (zh
Inventor
古贺义隆
大崎纪子
渡边学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Publication of CN106133519A publication Critical patent/CN106133519A/zh
Application granted granted Critical
Publication of CN106133519B publication Critical patent/CN106133519B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580015560.7A 2014-03-24 2015-03-06 Gip上升抑制剂的评价或选择方法 Expired - Fee Related CN106133519B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014-060341 2014-03-24
JP2014060341 2014-03-24
JP2015040187A JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP2015-040187 2015-03-02
PCT/JP2015/056603 WO2015146537A1 (ja) 2014-03-24 2015-03-06 Ｇｉｐ上昇抑制剤の評価又は選択方法

Publications (2)

Publication Number Publication Date
CN106133519A CN106133519A (zh) 2016-11-16
CN106133519B true CN106133519B (zh) 2018-01-09

Family

ID=54195063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015560.7A Expired - Fee Related CN106133519B (zh) 2014-03-24 2015-03-06 Gip上升抑制剂的评价或选择方法

Country Status (5)

Country Link
US (1) US10132795B2 (https=)
EP (1) EP3124966B1 (https=)
JP (1) JP6223376B2 (https=)
CN (1) CN106133519B (https=)
WO (1) WO2015146537A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6677455B2 (ja) * 2015-05-14 2020-04-08 花王株式会社 毛成長抑制剤の評価又は選択方法
US20230057222A1 (en) * 2020-01-17 2023-02-23 Rohto Pharmaceutical Co., Ltd. Method for evaluating and/or screening a control agent for tissue morphology and/or tissue function
CN116908157A (zh) * 2023-07-14 2023-10-20 杭州环特优检生物科技有限公司 一种评价药物和保健食品调节食欲的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
TR200100773T2 (tr) 1998-09-17 2001-07-23 Bristol-Myers Squibb Company Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
JP2004065194A (ja) * 2002-08-09 2004-03-04 Sumitomo Chem Co Ltd 脂肪細胞関連因子の分析方法
CN107141353A (zh) * 2009-03-05 2017-09-08 哈佛学院董事会 分泌的aP2及其抑制方法
WO2011007864A1 (ja) * 2009-07-16 2011-01-20 花王株式会社 血中ｇｉｐ濃度上昇抑制剤
JP5317919B2 (ja) 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP5328595B2 (ja) * 2009-10-05 2013-10-30 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
CN103298478A (zh) * 2011-01-12 2013-09-11 花王株式会社 血中gip浓度上升抑制剂、血中胰岛素浓度上升抑制剂、餐后血中甘油三酯浓度降低剂和血糖浓度上升抑制剂
JP6026723B2 (ja) 2011-02-22 2016-11-16 花王株式会社 Ｇｉｐ上昇抑制剤
JP2012171914A (ja) 2011-02-22 2012-09-10 Kao Corp Ｇｉｐ上昇抑制剤
CN102961388A (zh) * 2011-08-30 2013-03-13 三和淀粉工业株式会社 促进glp-1的分泌并且抑制gip的分泌的药剂

Also Published As

Publication number Publication date
JP6223376B2 (ja) 2017-11-01
EP3124966A1 (en) 2017-02-01
US20170227526A1 (en) 2017-08-10
EP3124966A4 (en) 2017-09-27
JP2015194481A (ja) 2015-11-05
CN106133519A (zh) 2016-11-16
WO2015146537A1 (ja) 2015-10-01
US10132795B2 (en) 2018-11-20
EP3124966B1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
Wen et al. Hypertrophic adipocyte–derived exosomal miR‐802‐5p contributes to insulin resistance in cardiac myocytes through targeting HSP60
Shimobayashi et al. Insulin resistance causes inflammation in adipose tissue
Brooks et al. Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansion to increase satiety
Zadjali et al. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high‐fat‐diet‐fed mice
Jeon et al. SREBP-2 regulates gut peptide secretion through intestinal bitter taste receptor signaling in mice
Vecchi et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice
Vidal et al. The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis
Yang et al. GPR119: a promising target for nonalcoholic fatty liver disease
Cao et al. PKR protects colonic epithelium against colitis through the unfolded protein response and prosurvival signaling
Arifin et al. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119
Kim et al. α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition CC chemokine receptor 2
CN106133519B (zh) Gip上升抑制剂的评价或选择方法
Hayashi et al. Adipose-specific CC motif chemokine ligand (CCL) 19 overexpression drives the mice to both insulin resistance and weight gain
Majchrzak et al. Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for the treatment of Obesity-Associated cancers
Kiefer et al. Intestinal retinol saturase is implicated in the development of obesity and epithelial homeostasis upon injury
Mirzoyan et al. A Drosophila model targets Eiger/TNFα to alleviate obesity-related insulin resistance and macrophage infiltration
JP6442403B2 (ja) 代謝調節のための方法および組成物
Zhang et al. Uncoupling protein 2 negatively regulates glucose-induced glucagon-like peptide 1 secretion
JP6514282B2 (ja) Ｇｉｐ上昇抑制剤の評価又は選択方法
Han et al. Activation of SIK2 inhibits gluconeogenesis and alleviates lipogenesis‐induced inflammatory response by SIK2‐CRTC2‐ACC1 in hepatocytes of large yellow croaker (Larimichthys crocea)
García-Martínez et al. Insulin drives glucose-dependent insulinotropic peptide expression via glucose-dependent regulation of FoxO1 and LEF1/β-catenin
Li et al. Myeloid PGC1β attenuates high-fat-diet induced inflammation via mitochondrial fission/mtDNA/Nlrp3 pathway
Hua et al. P38 MAPK pathway regulates the expression of resistin in porcine alveolar macrophages via Ets2 during Haemophilus parasuis stimulation
Mirzoyan et al. A Novel Drosophila Model to Investigate Adipose Tissue Macrophage Infiltration (ATM) and Obesity highlights the Therapeutic Potential of Attenuating Eiger/TNFα Signaling to Ameliorate Insulin Resistance and ATM
van Dierendonck et al. HILPDA uncouples lipid storage in adipose tissue macrophages from inflammation and metabolic dysregulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180109

CF01 Termination of patent right due to non-payment of annual fee